The real-world outcomes of multiple myeloma treated with elotuzumab, pomalidomide, and dexamethasone

Abstract

Background We present the outcome of relapsed/refractory multiple myeloma (RRMM) patients heavily pre-treated who received a combination of elotuzumab, pomalidomide, and dexamethasone (EPd) outside of clinical trials to evaluate the safety and efficacy of this combination in a real-world setting. Patients and Methods The medical records of 22 patients who received EPd for RRMM at our institution between January 2020 and July 2021 were reviewed. Results The median age was 73.5 years. The overall response rate was 55%. With a median follow-up of 20.2 months, the median progression-free survival (PFS) was 9.1 months (95% confidence interval [CI], 2.5–23.0 months). The median PFS was shorter in patients with a poor performance status (PS) than in those with favorable PS (2.5 vs. 10.8 months; P<0.01). Patients with prior daratumumab had significantly shorter PFS than those without prior daratumumab (2.1 vs. 23.0 months; P<0.01). In the multivariate analysis, poor PS (hazard ratio [HR]=4.1, 95% CI: 1.1–15.6; P=0.04) and prior exposure to daratumumab (HR=3.8, 95% CI: 1.1–13.8; P=0.04) remained significantly associated with shorter PFS. Conclusions Our results suggest that EPd is an active and well-tolerated regimen in RRMM, even in real-world patients. Furthermore, EPd may be useful, especially in daratumumab-naïve patients.